# Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct04879043/  
OnCo record `nct04879043` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of HDP-101 in multiple myeloma, run by Heidelberg Pharma AG, now recruiting.

## Summary

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma is a phase 1/2 interventional study registered as NCT04879043 by Heidelberg Pharma AG, with 78 participants planned, started 2022-02-07 and due to reach its primary completion in 2028-03. Interventions recorded: HDP-101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT04879043
- Phase: 1/2
- Setting: A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Patients With Plasma Cell Disorders Including Multiple Myeloma
- Sponsor: Heidelberg Pharma AG
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT04879043: https://clinicaltrials.gov/study/NCT04879043

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- companies: [Heidelberg Pharma](https://onco.cc/companies/heidelberg-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct04879043.json